bioRxivImmunologyPreprint
Adoptive cell therapy using T cell receptors equipped with ICOS yields durable anti-tumor response
Alexandre PL MarraffaiD, Cor BerrevoetsiD, Margherita Mosiello, Rebecca WijersiD, Daphne RoelofsiD, Mandy van BrakeliD, Kim KroeseiD, Marlies J. W. PeetersiD, Willem A. DikiD, André KunertiD, Rachel J.M. AbbottiD, Dora HammerliD, Christopher SchlieheiD, Reno DebetsiD
Abstract
Treatment with adoptively transferred T cells is challenged by limited longevity of therapeutic cells within tumors. To enhance the durability of anti-tumor T cell products, we have created T cell receptors (TCRs) with built-in co-stimulatory molecules. We observed that TCRs coupled to ICOS mediated exceptionally long-term responses including delay of tumor recurrence and cures in a mouse tumor model. TCR:ICOS T cells showed enhanced and antigen-specific production of inflammatory cytokines and resistance to exhaustion. Genetic ablation of ICOS-mediated activation of the PI3K-NF{kappa}B pathway neutralized the long-term anti-tumor effects. To translate TCR:ICOS to human T cells, we identified a single amino acid change in the cytosolic tail which was necessary for functional surface expression. Notably, the optimized receptor sustained performance of human T cells upon repeated stimulation across multiple antigen specificities. Collectively, we present a novel and uniformly applicable TCR:ICOS format that supports fitter T cell products for adoptive cell therapy. HighlightsNewly designed co-stimulatory TCR, with extracellular TCR-V and C domains coupled to CD28 transmembrane domain, and ICOS and CD3{varepsilon} intracellular domains (in short TCR:ICOS) provides:[tpltrtarr] durable anti-tumor response and T cell persistence in mouse model [tpltrtarr]inflammatory T cell phenotype and resistance to T cell exhaustion [tpltrtarr]effects via PI3K and NF{kappa}B activation [tpltrtarr]translation to human T cells upon single amino acid mutation in TCR:ICOS tail [tpltrtarr]extension to multiple clinically relevant TCRs while preserving prolonged T cell fitness O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=168 SRC="FIGDIR/small/682056v2_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@1ff752borg.highwire.dtl.DTLVardef@6579d9org.highwire.dtl.DTLVardef@22bdc4org.highwire.dtl.DTLVardef@d8c445_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: mouse
- organism: human
- assay: proteomics
- research focus: cancer & tumor microenvironment
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- approach: experimental assay
- approach: genetic perturbation / CRISPR
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ICOS limits memory-like properties and function of exhausted PD-1+ CD8 T cells
Étienne Humblin, Isabel Korpas, … Alice Oliffson Kamphorst·ImmunityPeer-reviewed·Sep 20, 2024
- Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies
Mansi Narula, Johannes Englisch, … Norihiro Watanabe·bioRxiv·Jul 17, 2026
- A signaling-optimized TIGIT chimeric switch receptor promotes metabolic fitness and antitumor efficacy of TCR/CAR T cells
Edite Antunes Ferreira, Kevin Jan Legscha, … Hakim Echchannaoui·bioRxiv·Oct 8, 2026
- A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system
A. Burlion, R. Ramos, … G. Marodon·bioRxiv·Jan 3, 2019
- A novel antibody targeting ICOS increases intratumoural cytotoxic to regulatory T cell ratio and induces tumour regression.
R. C. A. Sainson, A. K. Thotakura, … M. McCourt·bioRxiv·Sep 16, 2019
- Engineering antigen-driven co-stimulation and T helper cell activity into TCR-T cells with CD8-41BB fusion receptors enhances anti-tumor activity
Ivy Dutta, Justin Oh, … Aaron Prodeus·bioRxiv·Jul 28, 2026